Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Zenas BioPharma, Inc.(US:ZBIO) Globenewswireยท2025-08-12 11:05- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Cash, cash equivalents and investments of $274.9 million as of June 30, 2025, expected to provide cash r ...